Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$0.65
$0.03
$2.09
$857K0.22532,775 shs53.64 million shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$9.83
+1.8%
$7.67
$3.91
$13.99
$668.84M1.67816,551 shs332,554 shs
Fluidigm Co. stock logo
FLDM
Fluidigm
$3.66
$2.67
$7.51
$283.76M1.14968,838 shs60,126 shs
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$0.45
-5.0%
$0.42
$0.28
$3.60
$20.03M1.523.16 million shs628,680 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.58
+6.0%
$1.15
$0.85
$2.72
$480.14M2.169.86 million shs13.77 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
0.00%0.00%0.00%-93.77%-96.57%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+2.01%+19.93%+113.32%+14.08%
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00%0.00%0.00%0.00%0.00%
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
0.00%-3.04%+8.70%+11.42%-83.90%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
0.00%+22.48%+53.40%+28.46%+21.54%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.4642 of 5 stars
3.53.00.00.02.41.70.0
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
4.1338 of 5 stars
3.34.00.04.50.71.70.6
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.3265 of 5 stars
3.23.00.00.02.00.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
4.00
Strong BuyN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
3.00
Buy$25.67161.00% Upside
Fluidigm Co. stock logo
FLDM
Fluidigm
0.00
N/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
2.50
Moderate Buy$3.00572.65% Upside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.44
Hold$2.0630.45% Upside

Current Analyst Ratings Breakdown

Latest FLDM, PACB, AXDX, HBIO, and EYPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $1.50
6/17/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$28.00
5/29/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
5/16/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.00
5/15/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.25
5/15/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$1.80 ➝ $1.80
5/13/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$4.50 ➝ $3.00
5/8/2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
4/10/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
4/9/2025
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Sector Weight
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
$11.70M0.00N/AN/A($1.37) per share0.00
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$43.27M15.64N/AN/A$4.93 per share1.99
Fluidigm Co. stock logo
FLDM
Fluidigm
$130.58M0.00N/AN/A$1.24 per share0.00
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
$94.14M0.21$0.10 per share4.49$1.45 per share0.31
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$154.01M3.08N/AN/A$1.85 per share0.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
-$61.62M-$2.34N/AN/AN/A-471.83%N/A-191.66%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$130.87M-$2.41N/AN/AN/A-261.91%-54.27%-41.75%8/6/2025 (Estimated)
Fluidigm Co. stock logo
FLDM
Fluidigm
-$59.24M-$0.78N/AN/AN/A-45.36%-40.15%-14.86%N/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
-$12.40M-$1.32N/AN/A-63.51%-4.96%-2.24%8/14/2025 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$309.85M-$2.79N/AN/AN/A-430.93%-52.07%-15.82%8/6/2025 (Estimated)

Latest FLDM, PACB, AXDX, HBIO, and EYPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.19-$0.15+$0.04-$1.44$36.90 million$37.15 million
5/7/2025Q1 2025
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
Fluidigm Co. stock logo
FLDM
Fluidigm
N/AN/AN/AN/AN/A
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
N/A
1.50
1.34
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
7.85
7.79
Fluidigm Co. stock logo
FLDM
Fluidigm
0.68
1.45
1.03
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
N/A
0.81
0.40
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
7.05
6.68
5.87
CompanyEmployeesShares OutstandingFree FloatOptionable
Accelerate Diagnostics, Inc. stock logo
AXDX
Accelerate Diagnostics
22025.21 million14.13 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12068.81 million65.74 millionOptionable
Fluidigm Co. stock logo
FLDM
Fluidigm
61576.49 million74.27 millionOptionable
Harvard Bioscience, Inc. stock logo
HBIO
Harvard Bioscience
49044.21 million40.01 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730300.08 million292.58 millionOptionable

Recent News About These Companies

Pacific Biosciences: A Mountain Of Red Flags

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Accelerate Diagnostics stock logo

Accelerate Diagnostics NASDAQ:AXDX

$0.04 +0.04 (+∞)
As of 05/14/2025
This is a fair market value price provided by Polygon.io. Learn more.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$9.83 +0.17 (+1.80%)
Closing price 07/3/2025 02:34 PM Eastern
Extended Trading
$9.84 +0.00 (+0.01%)
As of 07/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Fluidigm stock logo

Fluidigm NASDAQ:FLDM

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Harvard Bioscience stock logo

Harvard Bioscience NASDAQ:HBIO

$0.45 -0.02 (-5.01%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$0.44 0.00 (-0.45%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.58 +0.09 (+6.04%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$1.58 0.00 (-0.06%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.